| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Innovative Medicine, R&D
2 companies
Reed John C serves as an EVP, Innovative Medicine, R&D at JNJ and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 5 sells. Those positions are worth an estimated $5.7M at current prices.
Historically, Reed John C's trades have earned a below-average insider score of 37/100 across 3 rated trades. On a 3-month view, 33.3% of the rated trades came out ahead, averaging -8.0% over three months.
The biggest single holding is JNJ (~$5.7M) as EVP, Innovative Medicine, R&D. The recent filings there lean toward selling, a net 94,789 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | JNJ Johnson & Johnson | EVP, Innovative Medicine, R&D | Sale+OE | 53,931 | $243.00 | $13,105,233.00 | -83.5% | -6.8% | - | |
| Oct 17, 2025 | JNJ Johnson & Johnson | EVP, Innovative Medicine, R&D | Sale+OE | 21,721 | $192.71 | $4,185,793.09 | -67.1% | +13.6% | - | |
| Jul 17, 2025 | JNJ Johnson & Johnson | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3,129,829.56 | -64.2% | +17.3% | - |